



Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31

October 24, 2022

NEW YORK and SALT LAKE CITY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its fourth quarter and full year fiscal 2022 financial results on Monday, October 31, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST).

Conference Call Details:

To participate in the live conference call via telephone, please register [here](#). Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Webcast Registration link: <https://edge.media-server.com/mmc/p/y9qtsbmx>

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc

James McCullough, CEO

www.renalytix.com

Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)

Gary Clarence / Daniel Adams

Tel: 020 7597 4000

Walbrook PR Limited

Paul McManus / Lianne Applegarth / Alice Woodings

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com